Strategies in the development of vaccines to prevent infections with group A streptococcus

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 11, 2013, Pages 2393-2397

  Good, Michael F ^a   Batzloff, Michael R ^a   Pandey, Manisha ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Group A streptococcus; J8 DT; Rheumatic fever; Rheumatic heart disease; Vaccination

Indexed keywords

M PROTEIN; STREPTOCOCCUS VACCINE; BACTERIAL ANTIGEN; CARRIER PROTEIN; EPITOPE; OUTER MEMBRANE PROTEIN; STREPTOCOCCAL M PROTEIN;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; BIOINFORMATICS; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; GENOMICS; GROUP A STREPTOCOCCAL INFECTION; HUMAN; IMMUNE RESPONSE; MOLECULAR RECOGNITION; NONHUMAN; PROTEOMICS; REVIEW; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; RISK BENEFIT ANALYSIS; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TRENDS;

ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; DRUG DISCOVERY; EPITOPES, B-LYMPHOCYTE; HUMANS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES;

EID: 84887460572     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25506     Document Type: Review

References (53)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5: 685-94; PMID: 16253886; http://dx.doi.org/10.1016/S1473-3099(05)70267-X (Pubitemid 41505357)
2. McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain that links the heart to the throat? Lancet Infect Dis 2004; 4: 240-5; PMID: 15050943; http://dx.doi.org/10.1016/S1473-3099(04)00975-2 (Pubitemid 38407307)
3. Massell BF, Honikman LH, Amezcua J. Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA 1969; 207: 1115-9; PMID: 5818242; http://dx.doi.org/10.1001/jama.1969.03150190037007
4. D'Alessandri R, Plotkin G, Kluge RM, Wittner MK, Fox EN, Dorfman A, et al. Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. J Infect Dis 1978; 138: 712-8; PMID: 3 682 61; http://dx.doi.org/10.1093/infdis/138.6.712 (Pubitemid 9110637)
5. Fox EN, Waldman RH, Wittner MK, Mauceri AA, Dorfman A. Protective study with a group A strep-tococcal M protein vaccine. Infectivity challenge of human volunteers. J Clin Invest 1973; 52: 1885-92; PMID: 47196 68; http://dx.doi.org/10.1172/JCI107372
6. Food and Drug Administration, HHS. Revocation of status of specifc products; Group A streptococcus. Direct fnal rule. Fed Regist 2005; 70: 72197-9; PMID: 16323338
7. Food and Drug Administration, HHS. Revocation of status of specifc products; Group A streptococcus. Direct fnal rule. Fed Regist 2005; 70: 72197-9; PMID: 16323338
8. Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1989; 2: 285-314; PMID: 2670192 (Pubitemid 19181596)
9. Steer AC, Danchin MH, Carapetis JR. Group A streptococcal infections in children. J Paediatr Child Health 2007; 43: 203-13; PMID: 174 44820; http://d x. d o i.o r g/10.1111/j.14 4 0-175 4. 2 0 0 7. 010 51. x (Pubitemid 46570082)
10. Smeesters PR, Mardulyn P, Vergison A, Leplae R, Van Melderen L. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development. Vaccine 2008; 26: 5835-42; PMID: 18789365; http://dx.doi.org/10.1016/j. vaccine.2008.08.037
11. Dale JB, Penfound TA, Chiang EY, Walton WJ. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 2011; 29: 8175-8; PMID: 21920403; http://dx.doi.org/10. 1016/j. vaccine.2011.09.005
12. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, et al. Safety, immunoge-nicity, and effcacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995; 171: 1576-85; PMID: 7769295; http://dx.doi.org/10.1093/ infdis/171.6.1576
13. Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin Diagn Lab Immunol 2005; 12: 833-6; PMID: 16002631 (Pubitemid 40993282)
14. Brandt ER, Hayman WA, Currie B, Pruksakorn S, Good MF. Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Vaccine 1997; 15: 1805-12; PMID: 9364687; http://dx.doi.org/10.1016/S0264-410X(97)00178-3 (Pubitemid 27449814)
15. Ji YD, Carlson B, Kondagunta A, Cleary PP. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun 1997; 65: 2080-7; PMID: 9169735 (Pubitemid 27237281)
16. Zabriskie JB, Poon-King T, Blake MS, Michon F, Yoshinaga M. Phagocytic, serological, and protective properties of streptococcal group A carbohydrate antibodies. Adv Exp Med Biol 1997; 418: 917-9; PMID: 9331798 (Pubitemid 27438576)
17. Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 1997; 9: 1723-33; PMID: 9418133; http://dx.doi.org/10.1093/intimm/9.11.1723 (Pubitemid 27494135)
18. Kapur V, Maffei JT, Greer RS, Li LL, Adams GJ, Musser JM. Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci. Microb Pathog 1994; 16: 443-50; PMID: 7830531; http://dx.doi.org/10.1006/mpat.1994.1044
19. Shet A, Kaplan EL, Johnson DR, Cleary PP. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. J Infect Dis 2003; 188: 809-17; PMID: 12964111; http://dx.doi.org/10.1086/377700 (Pubitemid 37176026)
20. Valentin-Weigand P, Talay SR, Kaufhold A, Timmis KN, Chhatwal GS. The fbronectin binding domain of the Sfb protein adhesin of Streptococcus pyo-genes occurs in many group A streptococci and does not cross-react with heart myosin. Microb Pathog 19 9 4; 17: 111-2 0; PMID: 78 61955; http://dx.doi.org/10.1006/ mpat.1994.1057 (Pubitemid 24342608)
21. Rodríguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, Mora M, et al. Characterization and iden-tifcation of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006; 24: 191-7; PMID: 16 415 855; http://dx.doi.org/10.1038/nbt1179 (Pubitemid 43221703)
22. Zhang S, Green NM, Sitkiewicz I, Lefebvre RB, Musser JM. Identifcation and characterization of an antigen I/II family protein produced by group A Streptococcus. Infect Immun 2006; 74: 4200-13; PMID: 16790795; http://dx.doi.org/10.1128/IAI.00493-06 (Pubitemid 43993354)
23. Henningham A, Chiarot E, Gillen CM, Cole JN, Rohde M, Fulde M, et al. Conserved anchorless surface proteins as group A streptococcal vaccine candidates. J Mol Med (Berl) 2012; 90: 1197-207; PMID: 22527883; http://dx.doi.org/10.1007/s00109-012-0897-9
24. Chan AH, Tan HC, Chow AY, Lim AP, Lok SM, Moreland NJ, et al. A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycopro-tein. PLoS One 2012; 7:e33451; PMID: 22509258; http://dx.doi.org/10.1371/journal.pone. 0033451
25. Kelker HC, Itri VR, Valentine FT. A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein. PLoS One 2010; 5:e8555; PMID: 20052405; http://dx.doi.org/10.1371/ jour-nal.pone.0008555
26. Bessen D, Fischetti VA. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J Immunol 1990; 145: 1251-6; PMID: 1696296 (Pubitemid 20258732)
27. Jones KF, Khan SA, Erickson BW, Hollingshead SK, Scott JR, Fischetti VA. Immunochemical localization and amino acid sequences of crossreactive epitopes within the group A streptococcal M6 protein. J Exp Med 1986; 164: 1226-38; PMID: 2428914; http://dx.doi.org/10.1084/jem.164.4.1226 (Pubitemid 16031618)
28. Miller L, Burdett V, Poirier TP, Gray LD, Beachey EH, Kehoe MA. Conservation of protective and nonprotective epitopes in M proteins of group A streptococci. Infect Immun 1988; 56: 2198-204; PMID: 2456272
29. Lancefeld RC. Differentiation of group A streptococci with a common R antigen into three serologi-cal types, with special reference to the bactericidal test. J Exp Med 1957; 106: 525-44; PMID: 13 47 5 611; http://dx.doi.org/10.1084/jem.106.4.525
30. Pruksakorn S, Galbraith A, Houghten RA, Good MF. Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies. J Immunol 1992; 149: 2729-35; PMID: 1383324
31. Crater DL, van de Rijn I. Hyaluronic acid synthesis operon (has) expression in group A streptococci. J Biol Chem 1995; 270: 18452-8; PMID: 7629171; http://dx.doi.org/10.1074/jbc.270.31.18452
32. Pruksakorn S, Currie B, Brandt E, Martin D, Galbraith A, Phornphutkul C, et al. Towards a vaccine for rheumatic fever: identifcation of a conserved target epitope on M protein of group A streptococci. Lancet 1994; 344: 639-42; PMID: 7520963; http://dx.doi.org/10.1016/S0140-6736(94)92083-4 (Pubitemid 24274307)
33. Brandt ER, Hayman WA, Currie B, Carapetis J, Wood Y, Jackson DC, et al. Opsonic human antibodies from an endemic population specifc for a conserved epitope on the M protein of group A streptococci. Immunology 1996; 89: 331-7; PMID: 8958044; http://dx.doi.org/10.1046/j.1365-2567.1996. d01-754.x (Pubitemid 26380072)
34. Steer AC, Magor G, Jenney AWJ, Kado J, Good MF, McMillan D, et al. emm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine development. J Clin Microbiol 2009; 47: 2502-9; PMID: 19 515 8 3 8; http://dx.doi.org/10.1128/JCM.00312-09
35. Bauer MJ, Georgousakis MM, Vu T, Henningham A, Hofmann A, Rettel M, et al. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein. Vaccine 2012; 30: 2197-205; PMID: 22265945; http://dx.doi.org/10.1016/j.vaccine.2011.12. 115
36. Martin DR, Sriprakash, K. S. Epidemiology of group A streptococcal disease in Australia and NewZealand. Recent advances in Microbiology 1996; 4: 1-40.
37. Dale JB, Beachey EH. Multiple, heart-cross-reactive epitopes of streptococcal M proteins. J Exp Med 1985; 161: 113-22; PMID: 2578539; http://dx.doi.org/10.1084/jem.161.1.113 (Pubitemid 15169724)
38. Froude J, Gibofsky A, Buskirk DR, Khanna A, Zabriskie JB. Cross-reactivity between streptococcus and human tissue: a model of molecular mimicry and autoimmunity. Curr Top Microbiol Immunol 1989; 145: 5-26; PMID: 2680297; http://dx.doi.org/10.1007/978-3-642-74594-2-2
39. Guilherme L, Oshiro SE, Faé KC, Cunha-Neto E, Renesto G, Goldberg AC, et al. T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infltrating T lymphocytes in rheumatic heart disease patients. Infect Immun 2001; 69: 5345-51; PMID: 11500404; http://dx.doi.org/10. 1128/IAI.69.9.5345-5351.2001 (Pubitemid 32786466)
40. Cunningham MW. T cell mimicry in infamma-tory heart disease. Mol Immunol 2004; 40: 1121-7; PMID: 15 0 3 6 918; http://dx.doi.org/10.1016/j. molimm.2003.11.023 (Pubitemid 38221194)
41. Guilherme L, Cunha-Neto E, Tanaka AC, Dulphy N, Toubert A, Kalil J. Heart-directed autoimmunity: the case of rheumatic fever. J Autoimmun 2001; 16: 363-7; PMID: 11334505; http://dx.doi.org/10.1006/jaut.2000.0487 (Pubitemid 32566127)
42. Martins TB, Hoffman JL, Augustine NH, Phansalkar AR, Fischetti VA, Zabriskie JB, et al. Comprehensive analysis of antibody responses to streptococcal and tissue antigens in patients with acute rheumatic fever. Int Immunol 2008; 20: 445-52; PMID: 18245783; http://dx.doi.org/10.1093/intimm/ dxn004 (Pubitemid 351321252)
43. Goldstein I, Halpern B, Robert L. Immunological Relationship between Streptococcus a Polysaccharide and Structural Glycoproteins of Heart Valve. Nature 1967; 213: 44; http://dx.doi.org/10.1038/213044a0
44. Guilherme L, Dulphy N, Douay C, Coelho V, Cunha-Neto E, Oshiro SE, et al. Molecular evidence for antigen-driven immune responses in cardiac lesions of rheumatic heart disease patients. Int Immunol 2000; 12: 1063-74; PMID: 10882418; http://dx.doi.org/10.1093/intimm/12.7.1063 (Pubitemid 30601369)
45. Guilherme L, Cunha-Neto E, Coelho V, Snitcowsky R, Pomerantzeff PM, Assis RV, et al. Human heart-infltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation 1995; 92: 415-20; PMID: 7634457; http://dx.doi.org/10.1161/01.CIR.92.3.415
46. Sampaio RO, Fae KC, Demarchi LM, Pomerantzeff PM, Aiello VD, Spina GS, et al. Rheumatic heart disease: 15 years of clinical and immunological follow-up. Vasc Health Risk Manag 2007; 3: 1007-17; PMID: 18200819
47. Pruksakorn S, Currie B, Brandt E, Phornphutkul C, Hunsakunachai S, Manmontri A, et al. Identifcation of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. Int Immunol 1994; 6: 1235-44; PMID: 7981150; http://dx.doi.org/10.1093/intimm/6.8.1235 (Pubitemid 24254128)
48. Guilherme L, Cury P, Demarchi LMF, Coelho V, Abel L, Lopez A P, et al. Rheumatic heart disease: proinfammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol 2004; 165: 1583-91; PMID: 155 0 9 52 8; http://dx.doi.org/10.1016/S0002-9440(10)63415-3 (Pubitemid 39435157)
49. Relf WA, Cooper J, Brandt ER, Hayman WA, Anders RF, Pruksakorn S, et al. Mapping a conserved confor-mational epitope from the M protein of group A streptococci. Pept Res 1996; 9: 12-20; PMID: 8727479
50. Pandey M, Wykes MN, Hartas J, Good MF, Batzloff MR. Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help. J Immunol 2013; 190: 2692-701; PMID: 23401589; http://dx.doi.org/10.4049/jimmunol. 1202333
51. Batzloff MR, Hayman WA, Davies MR, Zeng M, Pruksakorn S, Brandt ER, et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specifc antibodies to protection. J Infect Dis 2003; 187: 1598-608; PMID: 12721940; http://dx.doi.org/10.1086/374800 (Pubitemid 36578966)
52. Batzloff MR, Yan H, Davies MR, Hartas J, Lowell GH, White G, et al. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus. J Infect Dis 2005; 192: 1450-5; PMID: 16170764; http://dx.doi.org/10.1086/466528 (Pubitemid 41401160)
53. Batzloff MR, Hartas J, Zeng WG, Jackson DC, Good MF. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J Infect Dis 2006; 194: 325-30; PMID: 16826480; http://dx.doi.org/10.1086/505146 (Pubitemid 44116974)